0000950142-21-003867.txt : 20211202 0000950142-21-003867.hdr.sgml : 20211202 20211202171701 ACCESSION NUMBER: 0000950142-21-003867 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20211201 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211202 DATE AS OF CHANGE: 20211202 FILER: COMPANY DATA: COMPANY CONFORMED NAME: vTv Therapeutics Inc. CENTRAL INDEX KEY: 0001641489 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 473916571 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37524 FILM NUMBER: 211467776 BUSINESS ADDRESS: STREET 1: 3980 PREMIER DR STREET 2: SUITE 310 CITY: HIGH POINT STATE: NC ZIP: 27265 BUSINESS PHONE: 336-841-0300 MAIL ADDRESS: STREET 1: 3980 PREMIER DR STREET 2: SUITE 310 CITY: HIGH POINT STATE: NC ZIP: 27265 FORMER COMPANY: FORMER CONFORMED NAME: VTV Therapeutics Inc. DATE OF NAME CHANGE: 20150506 8-K 1 eh210206812_8k.htm FORM 8-K
0001641489 false 0001641489 2021-12-01 2021-12-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (date of earliest event reported): December 1, 2021

 

vTv Therapeutics Inc.
(Exact name of registrant as specified in its charter)

 

Delaware

(State or other jurisdiction

of incorporation)

001-37524

(Commission File No.)

47-3916571
(IRS Employer
Identification No.)

 

3980 Premier Drive, Suite 310

High Point, NC

(Address of principal executive offices)

27265

(Zip Code)

 

(336) 841-0300

(Registrant’s telephone number, including area code)

 

NOT APPLICABLE

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Class A common stock, par value $0.01 per share   VTVT   NASDAQ Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On December 1, 2021, (the “Effective Date”) Rudy Howard announced his resignation as Chief Financial Officer and as an employee of vTv Therapeutics Inc. (the “Company”), effective as of the Effective Date. In connection with Mr. Howard’s resignation, he did not express any disagreement on any matter relating to the Company’s operations, policies or practices.

 

In connection with his resignation, the Company entered into a resignation agreement with Mr. Howard (the “Howard Resignation Agreement”), pursuant to which Mr. Howard is entitled to a cash severance payment at a rate of $325,000 per year payable in monthly or bi-weekly installments through December 31, 2022, a potential discretionary bonus for the year ending December 31, 2021 to be determined by the Compensation Committee and continued medical coverage at the same cost as active employees through December 31, 2022. In addition, Mr. Howard’s outstanding options to acquire shares of Class A common stock of the Company that were scheduled to vest in December 2021 vested in full as of the Effective Date, all vested options will remain outstanding through the expiration of the original term and the remainder of his options will be forfeited. The payments under the Resignation Agreement are conditioned on a release of claims by Mr. Howard in favor of the Company as well as his continued compliance with his post-employment restrictive covenants.

 

The foregoing summary of the material terms of the Howard Resignation Agreement, is subject to the full and complete terms of the agreement, a copy of which is filed as Exhibit 10.1, hereto and is incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

Exhibit

Number

  Description
   
10.1   Howard Resignation Agreement
104   Cover Page Interactive Data File (embedded within Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

 

  VTV THERAPEUTICS INC.  
     
  By: /s/ Deepa Prasad  
  Name: Deepa Prasad
 
  Title: President and Chief Executive Officer  


Dated: December 2, 2021

 

 

 

 

 

 

EX-10.1 2 eh210206812_ex1001.htm EXHIBIT 10.1

 

EXHIBIT 10.1

 

SEPARATION AGREEMENT AND GENERAL RELEASE

vTv Therapeutics LLC (the “Company”) and Rudy C. Howard, his heirs, executors, administrators, successors, and assigns (collectively referred to throughout this Agreement as “Employee”), agree that:

WHEREAS, Employee desires to resign from the Company and his last day of employment is December 1, 2021; and

WHEREAS, the parties are entering into this Agreement and General Release (“Agreement”), and pursuant to the terms and conditions of the Employment Agreement between Employee and Company dated December 10, 2020 for the purposes of resolving any potential dispute between the parties, and addressing severance benefits for Employee; and

WHEREAS, TriNet HR Corporation provides human resources services, including but not limited to payroll and benefits services, to the Company;

NOW, THEREFORE, in consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, it is agreed as follows:

 

1.              Termination of Employment; Cooperation. Effective as of December 1, 2021 (the “Separation Date”), Employee has resigned from the Company and shall cease to serve as the Executive Vice President and Chief Financial Officer and has been relieved of all responsibilities for the Company. Employee’s employment with the Company is terminated effective as December 1, 2021. The Company agrees that it will not take the position before the North Carolina Division of Employment Security that Employee’s employment was terminated for misconduct connected with his work, and the Company will not assert that Employee is disqualified from receiving unemployment benefits. During the period from the Separation Date until December 31, 2021 upon request of the Company, Employee agrees to assist and cooperate (without additional compensation) with any work-related matters requested by the Company in order to assist in the orderly transition of any responsibilities that Employee has been handling. Such cooperation shall include effecting a transition of Employee’s relevant responsibilities, ensuring that the Company is aware of and has access to relevant information concerning matters on which Employee worked during the term of Employee’s employment (including any day-to day operation as well as historic strategic, financial and policy issues), and any other cooperation reasonably requested by the Chief Executive Officer of the Company or the Board of Directors of the Company.

 

2.              Confidentiality and Return of Property. Employee acknowledges that he is bound by the terms of the Employment Agreement, including, without limitation sections regarding confidentiality which he previously signed in connection with his employment with the Company. Employee agrees that he will continue to take all reasonable steps to assist in protecting the Company’s confidential information from improper disclosure. Employee agrees not to

 

 1 

 

 

disclose any information regarding the underlying facts leading up to or the existence or substance of this Agreement, except to Employee’s spouse, tax advisor, and/or his attorney.

Employee affirms that Employee will return all the Company’s property, documents, and/or any confidential information in Employee’s possession or control prior to December 31, 2021. Employee acknowledges that if, after December 31, 2021, he subsequently discovers in his possession any property belonging to the Company, documents or materials that relate to the Company or to its business with any of its products, research, experiments, clients or customers, Employee will notify the Company immediately and immediately deliver such property, documents and materials to Human Resources at vTv Therapeutics LLC, 3980 Premier Drive, Suite 310, High Point, NC 27265.

 

The confidentiality agreements and obligations contained in this paragraph are in addition to any other confidentiality obligations established by the statutes and common law of Delaware, as well as the provisions set out in any other prior confidentiality agreement between Employee and the Company, including those contained in the Employment Agreement.

 

3.                Consideration. Provided Employee has timely executed this Agreement without alteration and complies with its terms (including the cooperation provisions), the Company agrees to provide to Employee the following severance benefits:

 

a.Company will pay Employee severance payment in the amount equal to Employee’s Base Salary as defined in the Employment Agreement (on the basis of an annual salary of $325,000 per year (equal to $27,083.33 per month)) through December 31, 2022, subject to applicable taxes and withholdings. The applicable payment hereunder will commence paid by direct deposit to Employee’s bank account over usual payroll dates within 10 business days after the later to occur of the following (i) Company’s receipt of an original of this Agreement signed by the Employee, with Employee’s waiver of the remainder of the 47-day period provided below; and (ii) the eighth day after the execution of this Agreement, with Employee not exercising the right to revoke this Agreement during the 7-day revocation period provided below. This Agreement may not be signed until after Employee’s last day of employment and must be executed within 47 days from the date this Agreement was first presented to Employee.

 

b.Per the terms of the Employment Agreement, Company will reimburse Employer’s share of group health plan benefits premiums under the Company’s plan for the 12-month period following the date of termination per the terms and conditions provided for in the Employment Agreement. Further, to receive reimbursement, Employee must submit to Company on a monthly basis copies of the premium invoice from the COBRA administrator and proof of timely payment of premium and continuation of benefits. The Employee’s share of COBRA benefits premiums will be adjusted for the new plan year beginning January 1, 2022.

 

 2 

 

 

c.The Employee will receive a Cash Bonus (without pro rotation) as defined in the Employment Agreement for the calendar year 2021, based on the actual performance and as if he was employed for the entire 2021 year, if any, and shall be paid at the same time in 2022 that bonuses are paid to active employees of the Company.

 

d.The Employee’s outstanding stock option awards (“Option Awards”) to acquire shares of Class A Common stock of vTv Therapeutics Inc. (“vTv”) which were scheduled to vest in December 2021 (83,333 options) shall be fully vested on the Separation Date. In addition, notwithstanding anything in the Option Awards to the contrary with respect to a termination of employment, any previously unexercised vested Options (including those that vest on the Separation Date) held by Employee shall be exercisable until the last day of the Option Period (which for the avoidance of doubt shall in no event be more than the tenth anniversary of the date of grant) or such earlier date, if a Change in Control occurs and all unvested Options shall be forfeited as of the Separation Date.

 

4.                Benefits. Employee’s participation in each and all of the Company’s employee benefit plans and programs shall cease as of December 1, 2021 (or such earlier date if required under the terms of the plan), and he shall not be entitled to any further benefits or coverages under any such employee benefit plans, except that Employee’s medical, dental, vision insurances under the Company’s plan will continue through December 31, 2022 as provided in the Employment Agreement and contingent upon Employee making timely premium payments and maintaining eligibility for continuation of benefits.

 

Employee will receive from the health benefits plan administrator, a notice of his opportunities to continue to participate in each of the Company’s medical, dental, and vision insurance, and any other benefits through the provisions of COBRA. Employee may elect to continue his health insurance or other applicable coverages in accordance with the provisions of that notice. If Employee elects to continue to participate in any such benefits through the COBRA continuation rights afforded under any of the applicable benefit plans, Employee must timely complete any election forms and timely make any required premium payments and otherwise comply with the terms of such benefit plans. Employee shall have no continuation rights to participate in the Company’s benefit plans except as set forth in the applicable COBRA notices.

 

5.              Compensation. The Employee will receive all compensation, wages, bonuses, commissions, vacation, earned unused PTO, and/or benefits Employee earned through December 1, 2021, to be paid on the normal payroll date at his regular prorated salary rate, subject to applicable taxes and withholdings. Employee acknowledges and agrees that he is not entitled to any bonuses whether in cash or equity for any prior year and Employee is not entitled to any additional options to acquire stock of vTv.

 

6.                No Consideration Absent Execution of this Agreement. Employee understands and agrees that Employee would not be entitled to receive the monies and/or benefits specified in Paragraphs 3 and 4 above (other than any rights to COBRA continuation or vested

 

 3 

 

 

benefits), except for Employee’s execution of this Agreement and the fulfillment of the promises contained herein because there is no severance benefit to which he would be entitled without execution of this Agreement. Aside from the payment described herein, the parties agree that Employee is not entitled to any other salary, wages, bonus, commissions, PTO or vacation pay with respect to his employment with the Company for which he has not yet been paid.

 

7.               General Release of All Claims. Except as otherwise set forth in this Agreement, Employee, for himself and his heirs, executors, administrators, and assigns, hereby releases, acquits and forever discharges the Company, vTv, TriNet HR Corporation and their affiliates, subsidiaries, officers, directors, agents, administrators, servants, employees, attorneys, successors, parent, subsidiaries, assigns and affiliates (the “Released Party” or “Released Parties” and the Company, together with vTv and each of their respective subsidiaries and affiliates, the “Company Group”), of and from any and all claims, liabilities, demands, causes of action, costs, expenses, attorneys' fees, damages, indemnities and obligations of every kind and nature, in law, equity, or otherwise, known and unknown, suspected and unsuspected, disclosed and undisclosed, arising out of or in any way related to agreements, events, acts, omissions, or conduct at any time prior to and including the date Employee signs this Agreement.  This general release includes, but is not limited to:  (i)  claims and demands arising out of or in any way connected with Employee’s employment with the Company Group, or the termination of that employment; (ii) claims or demands related to Employee’s compensation or benefits with the Company Group, including but not limited to, wages, salary, bonuses, commissions, vacation pay, fringe benefits, expense reimbursements, incentive pay, severance pay, or any other form of compensation;  (iii) claims pursuant to any federal, state or local law, statute, or cause of action including, but not limited to, claims for discrimination, harassment, retaliation, attorneys’ fees or other claim arising under the federal Civil Rights Act of 1964, as amended; the federal Americans with Disabilities Act of 1990, as amended; the federal Age Discrimination in Employment Act of 1967, as amended (the “ADEA”); the federal Family Medical Leave Act, as amended; the federal Worker Adjustment and Retraining Notification Act, as amended; the Employee Retirement Income Security Act of 1974, as amended; North Carolina Equal Employment Practices Act (N.C. Gen. Stat. §143-422.1 (et seq.), as amended; North Carolina Persons With Disabilities Protection Act” (N.C. Gen. Stat. §163A-1 et seq.), as amended; North Carolina Retaliatory Employment Discrimination Law (N.C. Gen. Stat. §95-240 et seq.), as amended; (iv) all tort claims, including without limitation, claims for fraud, defamation, emotional distress, and discharge in violation of public policy; and (v) all claims for breach of contract, wrongful termination, and breach of the implied covenant of good faith and fair dealing, including claims arising out of an Employment Agreement, sales commission plan or incentive compensation plan applicable to Employee’s employment with the Company.  To the extent permitted by law, Employee also promises never directly or indirectly to bring or participate in an action against any Released Party under California Business & Professions Code Section 17200 or any unfair competition law of any jurisdiction.

Excluded from this Agreement are any claims which by law cannot be waived in a private agreement between an employer and employee.  Moreover, this Release does not prohibit Employee from filing a charge with the Equal Employment Opportunity Commission

 

 4 

 

 

(the “EEOC”) or equivalent state agency in Employee’s state or participating in an EEOC or state agency investigation.  Employee agrees to waive Employee’s right to monetary or other recovery should any claim be pursued with the EEOC, state agency, or any other federal, state or local administrative agency on Employee’s behalf arising out of or related to Employee’s employment with and/or separation from the Company.

 

8.                  Resignation. Effective as of the Separation Date, Employee resigns from all positions with the Company Group in his capacity as an officer, director, employee, consultant, trustee or otherwise and agrees to execute any documents reasonably requested by Company Group to effectuate the foregoing.

 

9.                 Acknowledgments and Affirmations. Employee affirms that Employee has not filed, caused to be filed, or presently is a party to any claim or administrative proceeding against the Company.

 

Employee affirms that Employee has been granted any leave to which Employee was entitled and requested under the Family and Medical Leave Act or related state or local leave or disability accommodation laws.

 

Employee further affirms that Employee has no known workplace injuries or occupational diseases.

 

Employee also affirms that Employee has not divulged any proprietary or confidential information of the Company and will continue to maintain the confidentiality of such information consistent with the Company’s policies and Employee’s agreement(s) with the Company and/or common law.

 

Employee further affirms that Employee has not been retaliated against for reporting any allegations of wrongdoing by the Company or its officers, including any allegations of corporate fraud. Both parties acknowledge that this Agreement does not limit either party’s right, where applicable, to file or participate in an investigative proceeding of any federal, state or local governmental agency. To the extent permitted by law, Employee agrees that if such an administrative claim is made, Employee shall not be entitled to recover any individual monetary relief or other individual remedies.

 

Employee affirms that all the Company’s decisions regarding Employee’s pay and benefits through the date of Employee’s execution of this Agreement were not discriminatory based on age, disability, race, color, sex, religion, national origin or any other classification protected by law.

 

Employee agrees that this Agreement is written in a manner that enables him/her to fully understand its content and meaning.

 

 5 

 

 

Employee agrees he is waiving and releasing claims (including those asserted under the ADEA) in exchange for valuable consideration identified above that is in addition to anything of value to which he is already entitled.

 

10.              Non-Disparaging Remarks. Employee agrees that he will not make any derogatory or disparaging remarks about the Company Group, its products, its management, its employees or any of other Released Parties. Employee further agrees that he will not make any announcements, press releases, or demonstrations regarding the Company. If at any time hereafter Employee disparages the Company Group or the Released Parties, Employee waives his rights under this Agreement. Employee agrees that he will not take any action to interfere with the conduct of the business or mission of the Company Group and the Released Parties. Employee agrees that he will not solicit, induce, urge or attempt to persuade any employees of the Company Group to pursue any claims against the Company Group and the Released Parties.

 

11.              Incorporation by Reference. Employee and Company agree that the provisions contained in Sections 4.7 (Section 409A), 5 (Restrictive Covenant Acknowledgements; Reasonableness), 6 (Covenants Relating to Ownership of Notes, Records and Documents), 7 (Non-Solicitation Covenants), 8 (Noncompetition Covenant), 9 (Covenant not to Disclose Confidential Information), 10 (Non-disparagement Covenant), 11 (Inventions Covenant), 12 (Property of the Company), 13 (Remedies), and 17.7 (Withholding Taxes) of the Employment Agreement are hereby incorporated into this Agreement by reference. For the avoidance of doubt, Employee agrees to continue to be bound by such provisions.

 

12.              Protected Rights. Notwithstanding any other provision in this Agreement or any other agreement that Employee may have entered with the Company Group (collectively, the “Agreements”), nothing contained in any of the Agreements (i) prohibit Employee from reporting to the staff of the Securities and Exchange Commission (the “SEC”) possible violations of any law or regulation of the SEC, (ii) prohibit Employee from making other disclosures to the staff of the SEC that are protected under the whistleblower provisions of any federal securities laws or regulations or (iii) limit Employee’s right to receive an award for information provided to the SEC staff in accordance with the foregoing. Please note that Employee does not need the prior authorizations of the Company /group to engage in such reports, communications or disclosures and Employee is not required to notify the Company Group if Employee engages in any such reports, communications or disclosures.

 

13.                Governing Law; Dispute Resolution.

a.It is the intent of the parties hereto that all questions with respect to the construction of this Agreement and the rights and liabilities of the parties hereunder shall be determined in accordance with the laws of the State of Delaware, without regard to principles of conflicts of laws thereof that would call for the application of the substantive law of any jurisdiction other than the State of Delaware.

 

 6 

 

 

b.Each party irrevocably agrees for the exclusive benefit of the other that any and all suits, actions or proceedings relating to this Agreement (a “Proceeding”) shall be maintained in either the courts of the State of Delaware or the federal District Courts sitting in Wilmington, Delaware (collectively, the “Chosen Courts”) and that the Chosen Courts shall have exclusive jurisdiction to hear and determine or settle any such Proceeding and that any such Proceedings shall only be brought in the Chosen Courts. Each party irrevocably waives any objection that it may have now or hereafter to the laying of the venue of any Proceedings in the Chosen Courts and any claim that any Proceedings have been brought in an inconvenient forum and further irrevocably agrees that a judgment in any Proceeding brought in the Chosen Courts shall be conclusive and binding upon it and may be enforced in the courts of any other jurisdiction.

 

c.Each of the parties hereto agrees that this Agreement involves at least $100,000 and that this Agreement has been entered into in express reliance on Section 2708 of Title 6 of the Delaware Code. Each of the parties hereto irrevocably and unconditionally agrees that (i) to the extent such party is not otherwise subject to service of process in the State of Delaware, it will appoint (and maintain an agreement with respect to) an agent in the State of Delaware as such party’s agent for acceptance of legal process and notify the other parties hereto of the name and address of said agent, (ii) service of process may also be made on such party by pre-paid certified mail with a validated proof of mailing receipt constituting evidence of valid service sent to such party at the address set forth in Section 15 of the Employment Agreement, as such address may be changed from time to time pursuant hereto, and (iii) service made pursuant to clause (i) or (ii) above shall, to the fullest extent permitted by applicable law, have the same legal force and effect as if served upon such party personally within the State of Delaware.

 

d.JURY TRIAL WAIVER. THE PARTIES EXPRESSLY AND KNOWINGLY WAIVE ANY RIGHT TO A JURY TRIAL IN THE EVENT ANY ACTION ARISING UNDER OR IN CONNECTION WITH THIS AGREEMENT OR THE EXECUTIVE’S EMPLOYMENT WITH THE COMPANY IS LITIGATED OR HEARD IN ANY COURT.

 

14.               Nonadmission of Wrongdoing. The parties agree that neither this Agreement nor the furnishing of the consideration for this Agreement shall be deemed or construed at any time for any purpose as an admission by the Released Parties of wrongdoing or evidence of any liability or unlawful conduct of any kind.

 

 7 

 

 

15.                Amendment. This Agreement may not be modified, altered or changed except in writing and signed by both parties wherein specific reference is made to this Agreement.

 

16.           Entire Agreement. This Agreement sets forth the entire agreement between the parties hereto, and fully supersedes any prior agreements or understandings between the parties, except the provisions of the Employment Agreement previously executed by Employee and incorporated herein by reference. Employee acknowledges that Employee has not relied on any representations, promises, or agreements of any kind made to Employee in connection with Employee’s decision to accept this Agreement, except for those set forth in this Agreement. Employee agrees that he may not assign his rights under this Agreement to any other individual or entity, but acknowledges it is binding upon his heirs, successors and assigns. The Company also agrees that this Agreement is binding on and shall inure to the benefit of its successors and assigns.

 

EMPLOYEE IS HEREBY ADVISED BY COMPANY TO CONSULT WITH AN ATTORNEY BEFORE SIGNING THIS AGREEMENT. PLEASE READ THIS DOCUMENT CAREFULLY BEFORE SIGNING IT. THIS IS A LEGAL DOCUMENT AND SIGNING IT WILL HAVE LEGAL CONSEQUENCES. BY SIGNING BELOW, EMPLOYEE ACKNOWLEDGES AND AGREE THAT:

 

·EMPLOYEE VOLUNTARILY AND KNOWINGLY INTENDS TO BE BOUND BY THE TERMS OF THIS AGREEMENT;
·THIS AGREEMENT SPECIFICALLY CONTAINS A RELEASE OF ANY AGE DISCRIMINATION CLAIM THAT EMPLOYEE MAY HAVE THAT HAS ARISEN UNDER THE AGE DISCRIMINATION IN EMPLOYMENT ACT AT ANY POINT PRIOR TO THE EXECUTION OF THIS AGREEMENT;
·EMPLOYEE HAS BEEN GIVEN NO LESS THAN TWENTY-ONE (21) DAYS FROM THE DATE THIS AGREEMENT WAS FIRST PRESENTED TO EMPLOYEE TO MAKE A DECISION ON EXECUTION OF THIS AGREEMENT;
·TO THE EXTENT THAT EMPLOYEE SIGNS THIS AGREEMENT IN LESS THAN FORTY-SEVEN (47) DAYS (THE CONSIDERATION PERIOD), EMPLOYEE HEREBY KNOWINGLY AND VOLUNTARILY WAIVES THE REMAINDER OF THE FORTY-SEVEN (47) DAY PERIOD;
·THE COMPANY SHALL HAVE NO OBLIGATION TO MAKE SEVERANCE PAYMENTS TO EMPLOYEE IF EMPLOYEE DOES NOT EXECUTE AND DELIVER THE AGREEMENT WITHIN FORTY-SEVEN DAYS FROM THE DATE THIS AGREEMENT WAS FIRST PRESENTED TO EMPLOYEE (CONSIDERATION PERIOD).
·EMPLOYEE ACKNOWLEDGES THAT HE HAS RECEIVED THE DISCLOSURES SET FORTH ON ANNEX A.

 

 8 

 

 

UPON SIGNING THIS AGREEMENT, RETURN IT TO COMPANY’S HUMAN RESOURCES DEPARTMENT, ATTENTION: Vanessa McDade. IF EMPLOYEE TIMELY EXERCISES EMPLOYEE’S OPTION TO REVOKE THIS AGREEMENT DURING THE SEVEN-DAY PERIOD:

 

·EMPLOYEE MUST NOTIFY THE HUMAN RESOURCES DEPARTMENT IN WRITING WITHIN SEVEN (7) DAYS AFTER SIGNING THIS AGREEMENT;
·EMPLOYEE SHALL NOT RECEIVE ANY SEVERANCE OR SEPARATION PAY AND EMPLOYEE’S EMPLOYMENT SHALL STILL BE TERMINATED; AND

 

EMPLOYEE AGREES THAT ANY MODIFICATIONS, MATERIAL OR OTHERWISE, MADE TO THIS AGREEMENT, DO NOT RESTART OR AFFECT IN ANY MANNER THE ORIGINAL UP TO FORTY-SEVEN (47) CALENDAR DAY CONSIDERATION PERIOD.

 

EMPLOYEE FREELY AND KNOWINGLY, AND AFTER DUE CONSIDERATION, ENTERS INTO THIS AGREEMENT INTENDING TO WAIVE, SETTLE AND RELEASE ALL CLAIMS EMPLOYEE HAS OR MIGHT HAVE AGAINST THE RELEASED PARTIES. EMPLOYEE AGREES THAT HIS EXECUTION OF THIS AGREEMENT PRIOR TO THE EXPIRATION OF THE FORTY-SEVEN DAY PERIOD WAS HIS VOLUNTARY ACT.

 

The Parties knowingly and voluntarily sign this Agreement as of the date(s) set forth below:

 

 

      vTv Therapeutics LLC  
           
By: /s/ Rudy C. Howard   By: /s/ Robin E. Abrams  
  Rudy C. Howard     Robin E. Abrams  
        Executive Chair, Board of Directors  
           
Date: December 1, 2021   Date: December 1, 2021  

 

 

 

 9 

 

 

 

 

EX-101.SCH 3 vtvt-20211201.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 vtvt-20211201_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 vtvt-20211201_pre.xml XBRL PRESENTATION FILE XML 6 eh210206812_8k_htm.xml IDEA: XBRL DOCUMENT 0001641489 2021-12-01 2021-12-01 iso4217:USD shares iso4217:USD shares 0001641489 false 8-K 2021-12-01 vTv Therapeutics Inc. DE 001-37524 47-3916571 3980 Premier Drive Suite 310 High Point NC 27265 336 841-0300 false false false false Class A common stock, par value $0.01 per share VTVT NASDAQ false XML 7 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover
Dec. 01, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 01, 2021
Entity File Number 001-37524
Entity Registrant Name vTv Therapeutics Inc.
Entity Central Index Key 0001641489
Entity Tax Identification Number 47-3916571
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 3980 Premier Drive
Entity Address, Address Line Two Suite 310
Entity Address, City or Town High Point
Entity Address, State or Province NC
Entity Address, Postal Zip Code 27265
City Area Code 336
Local Phone Number 841-0300
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Class A common stock, par value $0.01 per share
Trading Symbol VTVT
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://vtvtherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports eh210206812_8k.htm eh210206812_ex1001.htm vtvt-20211201.xsd vtvt-20211201_lab.xml vtvt-20211201_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "eh210206812_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "eh210206812_8k.htm" ] }, "labelLink": { "local": [ "vtvt-20211201_lab.xml" ] }, "presentationLink": { "local": [ "vtvt-20211201_pre.xml" ] }, "schema": { "local": [ "vtvt-20211201.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "VTVT", "nsuri": "http://vtvtherapeutics.com/20211201", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "eh210206812_8k.htm", "contextRef": "From2021-12-01to2021-12-01", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://vtvtherapeutics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "eh210206812_8k.htm", "contextRef": "From2021-12-01to2021-12-01", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 14 0000950142-21-003867-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950142-21-003867-xbrl.zip M4$L#!!0 ( ""*@E,D?W9UH10 /]J 2 96@R,3 R,#8X,3)?.&LN M:'1M[1UK=]HZ\GO.R7_0LGOWI&?#PX:$D*3L(4 2F@12(,UMO^3(M@ GQG;] MX)%?OS.2#3:8O KI;??>WC9@2:/1O&.!Q[T@[ZF^S$U\#S[,)L=C\>9<3YC.?VL5"J5LA/L MDQ*=#B>)_>1<3LK^>77940=L2-.ZZ7K45-ELD*&;#ZOA8^NLJ^(8>JPK/@DG MR6>70$.K-A\0[;R?%8VQKEYBUSW1U0N[ZJY5D*7B4WB('K,!DU5])<095LC^ M/&E?SKM[R?WG7;.>0TVW9SE#Z@$/$=)>.B>GY?T(D+3+U!@@^)[I6Z-GX1RD M\U((9XDY\95BLT+=&<4UMD#N<$YH@!'R#*[#>BO![F>A->SHN^D^I?:L@#G49KZGJVY&M89\B 3$3W&M8U2#GP3_._9TSV#EXZSX":U#YE&" MH-+LNZ^//J:JENDQTTMWIS:P017?/J8\-O&R0CFS."X;@#W^1SI-3G5F:(>D MP[PCTJ1#=D@FVN2(-&K\PUU.KMS==/Z0:V>5RC7\0/1(.OW2T?G"':[X+F&E M=^%*7P&NL#<;]9;A>P=W#*0/E@'_UTT@Y+0*%'*HT3 U-KE@T[L<6*C]@E0X M*+T&;BD"MS)DI@9_O5.#]N]ZU'#9*T#MGP"Y:W?276 X!$QX]!H8\EUG0!WF MWLEWW$X*("Y_]AHX-<3E.H"57T)I)7#%TJ;$]:8&^YCJ@10>$BEG>Z2K#Z%+ MDXU)VQI22X. MQ]G8%#\RJS"R'U-@F \5"XP0-;F81/&)25&JS-L34 M:)@/7>YQ 37"W>CA@%M=5,MTJ$B9B:NE@F8/+,C'E*L/;8,)JQ%,%0Y(8H74+AS'.A]G3V7-=PY:>SAS"E\(2W5FU<1'GV>+@ M^739Q/F"V6R@KZ4M8P$QA>/5J,?*\R6$D.9M2\. E2L&A2V+:,40"!\&)(W3 MV3=U0610R"5J#AEU?8>5 \T]A#XAL+ I/@5"6P%?F(&54P1$X)W>/,?"!8GF>-3PD>7PVUC5O@"XB]T#I?&E(@^#>R@FQL M":^FSTN=7$@ 3@V2.R*HSVEJZ'UXI((M8@Z00"G?-!O=>HUTNI5NO7.L.-P" M=^K5FW:CVZAW2*59(_4_J^>5YEF=5%M75XU.I]%JACUO*YWS1O.LVVKNDEJF MFB%R;J\ UE I;Q[UD$3O,==IJWU%CEV;FMQZ8-!2RE5X+)9.URS51P>*P?"= M.@L;YP'D8_?KV;!X>^(4VRJ ^]$((CI?JGR0OEATU\=9Q+3\^[$!Q+)=;W9) MNW[=:G=#(;R^:7=N*O"XVR(@NEV03R+E2:M-I+V=V@?2.B7=\WJ"<,\$NU+M M8B^IE"_\?D3#6=#U$ZM'VLRV'(_L:,%W1L&L,]Z^MEX\AC!MH=#H%Y)F9I!@QQ%+E M&E/94(%X3MHE"/C_1%TX]R*00Q^UCTXJ@;WY@+TB06FSONYBI<;#A"V9N];7 MWE#U3YO%F_LUF+6D>5/E47=$NI&$?GNK8:J9)UDH/L*G0./QZ4Y]0E6/SX9R M[\QF(=0EKLU4#-HUH@-!/)>H$$0!$3]LF$4+3MZCBL&@T3!@!2JOB^92_+M- M-2W\GL#1W$)P,XM95,LPJ.U"G_"3B'://2>$,V(.D)4:(6X0 X41\;&GA;T" MX/G"'[/&S=FK!;DLQ.02N&\Y8*5X[;#C@8)719VL:FDKQ+3:/1]6+F0Z&J&PPX!;XD6=*F6N5<\GJJ[;.U M&<3YG%APD-+YXIY<^*EB4[6&0]W%?1R"R)&FE7F">R^?>WFRX)EN8EGED!0R M>Q%+QXW12B^76^'E3F(,[=))(RC9J%P,G^+N@ZRYO0=3R:F#M7%W!0*ID_;WBRG EZMT:;8AFA[9A34&/PY8XX(!-@9P I^ ?)TCFN>K$CHT-!6'T=42874O^I:LWT^J^VN0B.A\X.GR^RLDX,.2+3L-,+ZT0-6N M!Y;Y9!;0>7"_W=[?W'_K%M> ]>*Y#\U'* S4$%R^$%"?A*A7T#8O>P:F7V&;@&=&W;6P9UPXKN+TWU>]^%+&:: M*E<'3'T@WH 1:MN.!0X3RQ>*-2$*,ZPQD@ ;D5#D('U!>KK!A4]W010]!DFD M!@D D&?H&QXUF>6[QI2XD!VYO2D?*D802X&91=)D"9B1>J$/<(#NYC1LZT$: M8HUQ'-:#=,R+7;)SK)==QG!;M'S&3.90 RN7 ,/G]152R<@9@?>'PTT3[M>I M,[Y\W>,!1/-I7 ##DSMCAT8RNS]6$&*I6O"R\T*K:@BWCNZ!7&$]Q#>#--M- M]@FE@_-/I:]?KZS\WEHV0E:=YDE$"26@5"P4CE9ZC'E58$WUFX#D,Y:4]IXM MU@2H SFBN!/;=UP?%0]4%_?.24'>"Y00M:\#L3(,U &QBNJ1':E(JJ=M(N=S M&>CXFQ<\?D?E*@7*U;$,707&FOTK,/-@ZXUDS3(?^XU/9Y>#0?'M-=>7:-8R M/K^&6LWQ!LD5B"_KE%2@0(N(6M4G(IJ(*U4AEQ$]_]:K7TZOPM,JUPY#[X G M*_DA$HR+G%:OMRJ;T2]Z-)G6B;Y_Z]T&]&YM*B8GJUC#=7WF/*MHE;94NK*_GGKLX#T5;0F[=U*W M36I6GJ4+.^K+-"OH^_Z:]>, ([&O2%"9 RENE!S0@V>;$CJZ3VI;TFP!E6>+D:)V M^(\YNY+@O0L=Y.*9>RX'WX_*N2?IT(S.*S&A8&%!@RT&=P9 M/)FK?++IVIP[?=5Q0W$08\%3YL(D3UBPJ20K7/97; A^+[34J[W)ERNZAH+Z MXIRI=$;,)4&>]O_FZT+2X(>AB'K#Y4RUH' M[L&%?:&[;]\%73RMB,9C^:!B$DY@=2J=6N7S"CZ0*K5UCQKDBCH/S/L%8Z:& MJ6'@R(@R)2K?4( .#V!2&3\#N5#LUUT"[(2H$V'T2=^QQMY@>PL,A8T[ -0E M&NOIIC@Y+*J3N;TPSEHH3<)3J93/DQU<4_$(-\YRTA$O5(9C='[TV,:CQ[C' M(X)964G+"2!#KFUOS8$7%H%C@#L?'P&?V5P ^., ZW%ZDY#O&IM%+4,E01'#3.5&_]<5]O.VM 6@O,R!! NTU M+9XN^2[CW8"-P78AOJI"YRF4N"B+W..3&5.$(TZFBLV"K5(KK:]%4W6\CMTEJQ%$]?,VS5@)C-Q=KSV M:F4^X6KE8J'GN:N5D4@Z,=*6[0U938L4GH24CK*Y/T$)HM+0\LW5:-*-QEVR@[X"HSXY=U3O]9"^(T;P M_B-_*!U]V-YJ^]J4G%MC<$'@LTQP2RJX((P*'>;"6L2)%_"*U8'.>J!)H0\+ M* J#-&SF[I??->#,7KRA1_""7@RA('(),=G=WF(S%*D[\W0QM#, !D,J,Q 5 M[FFOG$RP@-FQLPCJNP2@:+KPYFQB\Y.UZ)PUW:5]AXGB,2X1GD$(!G'P]I;# M#,J],SA@Q"*"*X=OV4Q<4 +^V'PKE7&IMAT*B*G,74\DGV\WE'L1LWXF S M^)UB8XJ,5?3TF+$'^,+?[&88PL!X \?R^X.9ZFUOY87RR;LPB6WA"[!05T#6 M5(?ANBC8*,4R?9?'C$@"/BL$EBAN,Q4.P$BX$@7DEP&!ASRE5*8SVG.CA[3B M=Z] T?(3<[;8BD%NJ-]]L.DD>$\3&N:$\EJH](%@P6? M=\QP'$3MFA^P=H1WT_6(P>.4PJ=W>KYAK+0AP!G#"'N'*(YU>.:P(;J* MZ!)"4HCXW]:=V % R]%!CX"^R!UN".$I6@^$@YM,T \U)S:+@H<#G1[38?X, MVLA0,MW(SE2B)A"@'6JFH#]B;W)M@V31Y=*L&E0?NB BVUL118,E]>C(4+=>.G 2@)D'8?SJ MDC >R/] ,E 1E94%V+5P9^-*"G\D.;BNNZ-]6%S:7^D@BA"2YW>0E<5*1U0Z MUG"S:.6]A(!V:[S$M/H*!+_F$<[THJU4?@XGB2ROVY%=HNY:=F0/2B^Y3UYC M$-_IMGA'@E)>M?4Z7T/RPD#B<.#'E!Q;>3*(UW,OT60]O39T,4]NLZW2A?5L MM;T!XV-*Q,LEV4"6FM8AY0I_&9I6 M,4'@94,(\4'^Z2Q>IN)U#CL8:6M8G<:0$&**!G]UL\ #7^!,M. ]2Q\VLO'W MNGIG_N]ZYR;JG>]U<_29V3J-LV:E>].N=]YKQDVN;R&$NHX4.<3F%,^<9P7- M^(;O]E;L#&.PX;N[N&.-NUJ0/D^)2GW_]DU4&- 8BHP27W6EL $U M>F&M@:>EHL,N3RE\K/-P>-3W!I %/T(JNW'*K#W#>-$T(L(4EB,Q[5CG(491 MG'_9*TM6^(-H# &2^Z7[!=]SV*Y<7(:>Z3Z>';#O8]A0 _KY=ULZ3&F$W)M4-=JCV)BK2 \EJ(S0\%KEA> M(I 8NOS%0!L6!W&(]34H7F,56>-5+TALQ>9#??8.C&#SX7FLUY7UILHAG=:R M>8N%2'#0\PIF^!+*MT./NBZ#]9:L6R2Z6/E"Y*0]S;]1^1N5E:C\;"3V8T@\ MD1$4CDA+5.$/R26^ ^&ODB"L,UQ?&T47)"R+OUU/\-2[E%_[^CH.3.WYD M2KS[8/Y[/]BGR>G]E_K%^+[RN5W/?FY-'_=.'W+?K5&W:^F?;A\ZE[I2/%&J MBO+-?1@ZYZZAG!FC^K?;TV_?O/VK>K4UL91;^Z%U-GVL716^:M*-K%\_W%8O M[D>WG\9VT],J_OF0U:Y;;I'^IY[N_KYK?CJJ/%!CT)>*CS37+^QWM&_?C5)) M:IO?SI3&0-''Y__Y+$^^U.KJ]^;5=<'Q:Y=U[[39LLSZP!]Z(_/6N]KKUJA[ ML5^J&2>C3C;W6?WS)F=\$N3X'U!+ P04 " @BH)3+3K, T!+B![_+$H$JG&4$77(K7NKW_/DEL5A83:DN6>UO2$;: J MUY-G>1\_O.2_X=>7ZNPD\N MPNB]V'WQ\9=HDBX//[P\*SV2R=^S'7\>7L!C27AQF1T*YZT/QX/^V!W%SLQ? MA/.;][>/XU#0LVGX?Y*'#2T=??3^==(]ZH[AB^;>AY=',&ML_>/JF#88]J8K M8F>SMP_/[HK=0^%..9!1)A,:WH?SCR/OK#5LC;N#OFA]&GK>J0>S;_4[XI/7 M]X:MGAAZ/:\U\CZ\//_(,WBL=9O99A)ZV+1,H%#!]>%FJ WF(YCV^D MU".$QO$I>-G/WC_)HGXY\8:PLPVAAR:F,@T3F<(L8I@@3EO,DG@!8Y1"+3 M M"9F/HW(IX)20W0A.&7C@SD8B(3L=<0^[O[>X?XSM/.$">P]),LA&[\ M!*B&CD 878@PH@TL;AI,\9.,@-SF8BCGTD^EV%+;:)YR]A$>7^9)FOOP+K4& MNRJ314J_!'$T#;,P!@J"E<+?/+-:]9KM="*S:RDCNQGXLE[TJ9\!J=F%W:65 MW066D_#<\F09IY*Z@(V+YU@@SF8;I,L^DZG!_01;.D["OLS$R1 6"28/IQ?6N%Y;)O%5"'0L M+G/HEA8C3^ \PXR2JS# (811,,^G.,M)GHDHSL0\7(09G^6E?Y/ .:?5-U.W M[ZKM5?ORB$SZEB7H#[Y 6[@.QX.AA_-!(DMAUGH1%*$M\BR'C0_B*QD!;:;X M6.:'$*F$]W"6,3R:B(LXGM+'*W^>^Y.Y++;)1R@! @R7?$#2?#8+@U!& M ;& Z\LPN,2S14U/@$\$WZ+X>BZG%W(*]!42:R"6ARP5J&D^CZ_3!^%\U4MW MER"=Q//I W13M4.K*L2U1#WC/5!;LO#G+S[N-7EP#_4G:E&L69Q_' /O"2/: M-MP9RVX.@6[CI=I1E.=-)L4E?>78?996$&0.69V@#H0SJK!TM26KLF*C5V[G@X4E((1(@MP^!@.X%! MX5Z)S/\FF6G'*0D4F X,E;_KQPF,H^T#[X*>12>\"M.5_0>"#O(DS&Y038%. M;IV77Y@'KLDB3%&8Y4&&O"&"><$/-'\4G]=Q\HUEH;L:- EDL:!%R203A7Z! M*Z0HEGX#+A7.0DT/Q&5(@.61,R+-C9NBDY/HIK6 (QH[=&0)4"#]00M9.+Z")-HU#[4'+2EA"W72QE ME-(8MGEY:"%@>7: ]&@U%WX&:YOJ < WP#!)FS54!%N7 /-UN@Y99-/7H("" MOAHI.D!"CFY6";FPV/8 7,(D@$HNFF*4 \\.+$]01X\%)&I)3+VH2I3Z6R$= MF)J\0@6H/ K0M:-4;YB?E<^*?XTR@V; 9]0G[5N0!LI- IE$,^1&U#F0'ISI M"-O3RPC?LO@Q<\75AE6=6D)!6JX&03KNTLA6&.*U1 4A M1;('DR$,!!D/\B(,&F)FN ^IA7 < YQG"ONL5$5LFF6NN_()L#N@GPF9%D6J M4'S-LC[#UXIT*Q3?.HK!VB%6#4*GYBS!#<]NR):^%!"$H3XH.&G#>15V&7:9%%@OZ?*9[E]*-/>[WF MSD>X?(5$2+A8TA:A5 KF,? MN3I$%&=9?,<9^EX*G\M95B+O2FRJ3#3ZW/V4 M@RL/Z[]V=D!=D_/I>W'F7X!5.4+6!_P=SK+8V5&(X8=.]W,1)@.VO'PO?ET: MX&YG$F=9O%#?34A&FN^.YG!\Q/[R=P&&<3B%88Q;1SU/M+U>[ZS5Z73[G_[Q M8O<%?1Z=M=KZL^I2M8;HC[],86CZ7X= I-/L$OGE[M^KX+_Q4+ZK?PEW6]'Y1Z)SRU..27XR'^@6L.?\-F5NSK!$[UMQU6 M:-^#$8[$L,%>PRQ7$=1EYHJ?0H_N['#63&0_W0%Y"N&YT?@46Y2"=53+/:W M0*X+0@EU5/PX\X,LA?7P\<=Z+5\BNU:*BOP=F#81&'R1YI,T(\2)!)@+R"%< M&\@E@6LK^AMHFWDJ&R ??@."$]ZR6TB:V CA@GD011\X!:C\)L#I;9 M ^HEUBSR0<%#45Y4X$DD)JQ,H""LD&]BJ32,AIC&08Z+EYK5P#U;*_[":&5I MZS6P-%,$!%'G3T@:@WT)?80Q&28K9M6M&DLX@Y',@#6MOM= B8\$0 PG Y4" M"2V^0N4^!%4"]]$9"^&::J)@TLSCZ((H+RY:<68%<*<;BA.#/ MH8$_80B+D$8[H2=H)0>4I-IC(3: N$D3,&/N=K9[OBL6"\V]U\3U58K^OIG MOUE^H)*5%O#?I7]C]\=Z%N%K=ADS*_ 7<0Z?)*+!E9K>$3H$1O[<3VZ0A4UA M-R-D@;>P$K$5\X\3/PU3AAGA_Q%VD7)+\-W?#O9?-W9W=Q%-%C<@T\66&<7? M]M\T=M\>- \.Z%?@J]GE]K9V^1=4F7H-=)E]#""8_%L&I*WZ2Z#Z@+ *T$\5 M>\8C< EL!^@S90^ \YA>%/2BD1JMD1!0!WC10@)\IH3MP2*0-Z!JO8#B_>@; MXJFTKJA-B3S%:6D?)WJ5^43"$N[M6J5GZM^D2E?#Q4-5B32C. CR1 -,]I!M MA=LKBJAV%:+:Y*/Z& *-0M\KRKU&CY0@T[-@?&J5"*Y]TH34&$!M\4-:)?7% MJS<[B-$VFQ_([RX)W[5S9<:F4.ZR&5(8$N% \'@2 MA*GF7V3],G9]%9.[IC!5QJ/1^R(%#Q2?"Q2_JQHSTD>AB06\A!U/I%XX=G'P M#%:6:TV4!JF+.;H^)M+R!6(^TLP%^=^9(,FEFA3Y- EL[%*:Q5?T.[6O?T=XJ[&IV?XBZ%!'+SC MW%X69E8,MC&1(.R[O$W=%,=Y@@IO@P\N.A^EG3VOC#GT>&J0PR^8Z1K+$<0* M"P=0CEC8!/$RQ%@JM>)J.6 D5S&ZKJWK>W T;!6CT-AWE,3P*K[-*I>6#/"- M;DM-&3%RX^ZW;M*QPTZM4#![Q_VN;A=M/K %?XHDI-8/!QK!(: =(Q$YD4#I MY(;['Q^Z!TG*QOS^8QS]A[ '5_&Y=18B'ML-(.K]9XCZ"2#J_6>(^GM!EFIT M^B\F/8/-I*?+1+5<9 GAB[:?7HJC.,I3&PD"7%LD<:;"/ZR92!P>.;)UQTPG.EH-HV11!(X<#G%2WLB+: MX!%5P;\D-R! .$U-D/. OVW1MR:DGK;Z MMQQ)B92(E(R[-I@88!C@;B/HJ)J=K:+-W2AHFA[@5],NAQ1<2VPWN)33?,ZV MQ)5DE[ZQL3G<\.U!XP"L<1YYNLWT2X;,+)^#GG3%L3/JP)0"PIHP# .Y-M"2 MPH-K%@7(%4V@"WU:"PNAO07D!T&%A\Q!C'?2UKZKG9+B9TVNAO):F*")/%*V M(XQ5#9E[*X%B")O2T:/EJ)[5-AS].9G0%F91I[I>4]T0NL"V(MOTUC!T9GK& MNO<6[XEF(#ZHK%/MFYO&^20SD6*PA$)>,1P,"C"%(_J14LLC\IU$:+&GL&!& M%];*_$7B1]DV>_^@.V!-<_1"X,_,HT0;&KL@'M16WB?"(%C;QQ'D46GQ##N# MP<\DA77[AB65XU,?@S?] 5G[,V'2KWX0)GVD#(^-XY#+S(QR%X)P:?R7TL<( M=$4711E4BO:3%@XFBR;5!A<0Y"(M!""O"WJNHEDD60S>"Q."9:95AC=VIP(! M+Z7F70K003F=*>:'W&+&=JFUT<@=@_ I.E6Y WR.!Z)/?F%BUG5>&?"++D:0 M30V!) )_UVLJ;CC$F$T\\7>:[Z5 K0I$#-;:RP_%T#U[4J4YIVO.IR;(>DU1 M).>DE(BR'$AKAJK)K^3>U&A'TR6D&Z .);C-8#E#D*9O.@.IE:A^')S>GD/T MF08!6. D($V$8[%[.GZ\9*""V#!D'L-=*Z8/N75B%6;*2$Z!MLG&10Q_AM# MU&$6:N&=J9081A'J4B>-_'49I.:]# M\@A#PS=VV0RS)*96&%JSK-U<^E>(PI-'?F7JJZM816]%*:!XI<\.\1GE5&CO ME%TO7F[>S/1!PXI^;LW@]:/&3=NLB2:ENVP4C+'.-)\7\S :8!=?X.HH\[5! M_K20HHDP^?'*#]1S(,[9IY*C7GXV'ICH*7/R[-'E9U=$G@EJ A)49K76VWGH M!0<<1N8@VTGD13[W$\*M$\H240[*A+3A^SD5J\.PB&D6PZQ##FJU MZTM)G ]CNQ'M@(7 @ZW$*9LT&"5"> 6V;WI>T[*3*:,LN()=Z5B/?YTPD%]_ MD,K=1W^%$PDB6A/TW.G,DBJ?YWVU%6JO/L&4OAI' M(5-MX?RAN6SV>@0&G_LK)?0$.23@QKO::J!DQDX.<$2R)F2X)^M6 $LEJ3+,;\WN7U MVE]RR^B:HH6RRGK*E0F!MF$:).'$U#$H%?@P=57NU$982+"B5502BRHB:H(D M)'P=K./?J PW!_^](]F-ML;F=L_=19"$,X.>V.;)@4H%)Q)^ 7M%;%_G2Y)UH!,ZI" ME0NUEU/4/C-=JM) ? ML)4]H81=6^/^)&2WYU%\P,T6^L&!8D,,OW4P&]) !Z=R(;V'$U6T;]Q$VF5Y%1];3XW="ZO^:8EG2UI]-YM8"O<=C_R MQM/ U'8+M2) SE5+4BK\<:_**$2,#9W\EQ6KU)"XMF\?*O?;#>QHEY3C(#< MFN(7+#1QN/?J8.?5_GYS3VQ)4&Y2^5MS^]9NSD -0+'Q964?SU35!YZM%K?K M^OWUH+6S)T =6>VR7BOU.53$&RK>@,E=;7,N M+_1JQ+ Y=VQB%(MT%,[=+/%SE' 2-%2-8"]BA:].42\"98>U.:.>(?%>A?'< ML-YE#B(Y4+5J6$G94L/2_!?[0GN?]1(.@$&JND[BZ *,1Y>;Z]V=_=U:(HCVB':.TRSEA5"::D:?X;.$8*#(P= M.$=#*N>+?X+M@MJ)J=%5Q!\2]A:J36;CF!<+I%&D &+*^2&XUT=EZHJ\)BMI MJ+"-2N=G3X0V H;= K&"GIN&ZI2JS;+IK$J[ )[KJU;<@A2_>D:*GP I?O6, M%#_@*7OQPT_QID#T(_..S8JRWPUJN=JQYPW:6CLF:P_M_BL,AL^4U8*(3W!3 M5:;$FC5.1""'\**2 "U3@&FQ%?3V*1BB(!]*M;ZH$C:)GXJ*ASK7:8-:!(A,,1&88!E^T\9<* C%RTX!_VBL >> M75RQ1A-YZ2, N )WW&9.E]4>]L2BIFZBC\L%7)N;";K_'-_]VT?TW:_SXP^I M?.Z]BCF4J_A6!)$[VBG7YU49P&@'Z)*SJ7)ZK$ I>-I0GPK\I1]0F1!$E31X M:[%;B\LVJ,!T/L]\U-JS!',-90'G*\0/Q#I-F4MSZL(W]=JZPIG%X>'[M 0Y MYS)3>+B\B*D,ZE^&6-\].K&Z9-HRL4 M K&FQ+@Q"8"_1.' :>ISKCI+LN)&(V3,FY'G%ADJ& .!E)P9HNRK2E[W ^CF M.RL>;;2*Y(:DG S),FN.4!3+P%)]74PST[Y4W%=[]"QFIW M_'D%VW)%3QF6 MI&<85/15[#8&V"X6\52E;H!YB"';?ZIEU\'\MQ$Q.S: Q\;)MR48-FCDHV&M M$-(@R#G;@<$=J^T)J8 MK?3U8Z78X]##9F<%G0NIBAVDM\0A=HMT0+ MRKU0]D13;(IJPBEUKS!0YZ*8/$+X*XE;6(J%/W753H[JKXX*I?)%7'44SGDX M1=3-&%YTI<&ZN M%G5<.ZIH$@>8=6Q=7*KJMZ')A]GL)\KANIT"G!-67'^Z3>,ZP:,9,58./4<< M XV1;\@V\,Z"QDG *1? M/P/2?YISM E3XGPBA$M97YHB.H/^-<>/NU+;@"\&*AB.&"NQ39FBOP><_S^C MV-NJB\D$J^*4#\*9'ZQ\I&YM73)A36T'3"^"MF0A0AE!@3F0Q?3&:!Y/R/>> M]FZRW4=,].O'T4XG3*D,,F[&4,(4OJ6;YOS=>ET(ZAXF 14()+[@N W&$G27 M2)34)])+GJUBF0U1K/.-GV#IX0"K.U2RU"UV8])J63,IQWXZR7C&K-&^A;6# M1]=W#KQ0Q8HA=I7:^%O!X7!P#++$+U_8X@)4F&GL1B*B$5$L%&D6AL=31G55 MK%YY3FXYQ/D@VV(1=YPGRU3?GM M[0;HNUM#"=PC9)]06X=E66<\A#%K?MH3'#%[]56RUS86B0X1PU=T+@VLP M-M++<(E$WX\I)GTHL3 "0UP=[;/9;M1K,":4!",^62S)3;/0RUOZW0TVTK_" MC^_L$-1E3!2/1Q>3N!=PB:Z%Y."UO5WNU+ \MIJX+I_L5G98HRYVMNW%6#%<'1S?VIHZ((\95)BQ1_762L/<>\UJX,X-/<.CRIAR@ MOUJ?S%S.$)NJ*&7**" EOJ6N(FR.%5"H@@99<&Y 0E%:%>X]+Z29F!Y3FV(" MY_%2W1MGF9%3=\2^4Z]AW? U\786OE5%UV )9C/KN:8 90.>:S/!QML5;Z7U M3' )72,3HA5A0F 9R25W%\8S)JH2@^L=@ 8:G)"P9KBJ+!&ON+T[+JT>O==6 M %XB'>2*]"96PJ[Q9LFYG,SC:W>KTQ)ZB_?UZ75 EUAQ\/21,@,4OKP^@L74 MS5"5 +D@I>O0,*6;U(1P#CRI->5O'/?Z&8=8 F64LS(- !Y).57B#'-E_!QL MPR3\/V=_7+I\>6%\^M&%SQ'-!#4SU:@$C3Q2Z&"J# "S*55U*DR]&FBUXG8> MI8F%;N4>ZCMUZ_-L.("_$%-]Z!M.ZC7WDV6PG\AO@6>PYU\?HCI =]WC_4?S MW!25>;(BH7A?V&J=T+MAN^I*H7O-30J%WKT[OB7$#2J*WMU>EW 7BO=G$%FG MDBM_&&HVQ#^4\X)"!NA\N)G4!-8H4P]4U#RX(W==E[J"CT[^8E7?;)F: I%3 MR5D+2D:M,C$.-#!L.U-.$7NADL[.8.N;;Z0!O2U MI[MQ5GR PS&5-MG#YPH?=3%>1D7:;,B]<"/NA5/MI'*LQ9TNUKO\>1QBFX'U MOSZ#]4\ UO_Z#-;_&:^'^AGESN2!Y8Z'F68*,,J3;+WVF8Z0#X+^$8>N)"(I2BP[(ZT]0Y13S;UL]2*W2LMY>B1D(&)*@Z;YCQ,'#=*'(' MAA;8,K^6G"TJ44P77*^;///?1^"_P6/PWVI=?WVX"EV$-+_BJVD1(0#%_V^P MXG01G\-Q"N^8*&6-61$P2IYBXR,+&?TT$+C8?[/[%HN)I6M41662 M,VEJKC:L,#W"C%UG8##@Y;P@SJU[=?QJ;W M0#>BN"M#G3J=&KVZ2&WP-U"M+OS!B\R."$8 ]1K26KD%0D *8=$/I%J&"[=5 M& 5Q_H8F98P5P_LGJF) G>1Y# ?%^%Q5P9,ND6'B()' >=F4AZ.NK,%Q(?:Y M+.[?DBH]T-E2EQ+>VZI]EAR/(#FF#RPY/IQ__)_SX5]P=]$5KV!U!$^*\W_&&8C#$!]N#?M_CG[]TQR?P M8G*;\-#U-2_O/;Y&+I53!$&=WK6&WS%9^HU]2*0R>#T#/N#)GK= MT^'U/$^5S5 .%*&1.$D/F&#MR#/R?84ZUPI^S"/@KUC6Q8FVP8>P M3-O/F_6V&7KXYAD]? +T\,TS>OB?QL(?^CJ(M6G$6"Q+UZ+?)&AB_8W9BWA* ME@!HQG.V'Y'3*H5:U5 &71.3*$P$L[V>?.+F=EVK6LBJ&GU@8W%T8M,J,/@7 M\OM^WY4&[O9[?'GEO6\D*%$!F&"ILL'(-.=65ZM(K6(8#09 .5LFS=$TD5.% M':IP!1/3PL)3)]00EE?1L',IU^H]06NNQ;(W!]*-?GQANWOAGRHN:F/&=+'N M0IA8]<4@U?FTE%7'>5MTH8_*H.>0A@9%B5'Y,JY6XJR!51;,0;#A%I&N(8KZ M2G4149V_QC>#J)4JUC>V!<\1N(]O+X>\/OI8\P8N^GM7%'.Q:KB38XCZ%"8- M4)'0/"LN;DA>\0)@ZM1@M@6)W9K+?'FW"?FDW.=;D#3;O"JJK.Z5"Z,\D=J$ M=[P>=(W&FHY_6O5N77K7T4##TQZG[JHV%8-/Z:XJSGM4:>&'JM#O_6&;3/ MR2YLMX;>\7FOM])$%UZC1[$ET?,^@3UJWD([5CU8KW7'8''V>N*D]=E3#^) MO?\]]_IM;]3$2>A6C[S>X$M#F!FWVF@.][S.)["3L54:-'3<&K__\/+H8;9Q MLQ26__2+=]<7T1O=+$#:PH+\]][;@\-[(20.\7X>],[[X]:PNX)S=/MCK]\9 M(04?>>)H<-XGPD:@8>P-3T=B<%RBV$/>^TI4['F?_M ^E?"@T9G7[AYWVRT\ M^G!]KMMPA=:O=:W5,ZH?88G[:^TO&O MU^C[D]:(,"JOKR JW.J*IKI]!WY"< L8&G5[-@":$6?#+L)6 Q>Y@K>>J>4' MGFK/AX)0V MK-,:>V44\@NT=MP=CG!O/2"/L=_UA. MH0_<&+>L>-!1CH_*NPK'V!(%*!% $R/$K,76JS>**K885>Z/NL .Z/#7:V<> MG._.MJ,-*.7'2@Z4(ZY<(<1\1,,;>J? L@C_/J8OJCH6W,@M%) M2ZM_P!\&1SUT&.!IU:<9-V78 F50G+6(UY,N8-7>8_OOS@#VMS\8JS-/[I$. M,(,>NE:4'#'.SD_!<4$V,;@?-@& MYM'QT#//;[;&J.4 IW]?Q&1I&%GB1RDFD;T7^7(ID\!/Y8N/GWU,)?;%:=#Q MIU+QO&9!BHV[IQZH*R##AJ#%>B/SBQW4X$R+R*'W>?#/%3G5.1_R3%E\]G>L M.O/HR @LM][31^^HT,6S(/T^07IZ#GH-:$_=8X97UE,^*NU?AMTQTIC2HY3J MK%7VUO$8-"Z#\CV;73]J$UF=1AU8J3\$B5@=>@ SPWU4"FJ+S:0RAW&1%6YQ M-.[V>O7:$:-NB,%XG4-\=]U>/N*)_[&X.I&MTBQQ+4\''<*^< %'#;!18$&Z M+5@;6-H!G)OA%V#:^'W'8_BI*&TZ [4[(S!+*;2J=7SLM<7]T1!S"0P!XP2--!&&/<\:E.CFG@,"+\LV MG M>L .]TH=?N_2?#RZ>5_5724PL;?,-##Q,GTIAOGT1K2;XB3&0AYWTIFA-$A^OLGX<,JD:]?WF6-7 TXW]#W_E<>5EK-9UZ8=)0QS%6', LR'T MO=A_BGG<_M5W&M-N]%1P9R,9&)V&N(_=W]O?LPQ/NUH ?_D^*FCR,S M'W),MV.Z[P[%8$G!9^]%ST^S9XCW"2#>=S\4XOW!@.MC/_+R:-#Y2ASB9'S: M^_C_ 5!+ P04 " @BH)3[=PGJS<# "# $0 '9T=G0M,C R,3$R M,#$N>'-DM5;;6ZXR :>Z@.T3$I^SQOEOH3H2(>,.VY_.Y1>@, MSBE[X99'I[L)#@04,2_4G,3)GMWH?[QT_B6G,:7D#SW;^&G M3LV[JR?/T0(_OR2S[]&G+P'Y^K3XQOR9LZBU?UV?C*/I:?#C)@W9Y-X$32&0 MAT%XRU#U9>7-CRS*QG;-<5S[J=\;:)R1 AM)B,E+&=RMU^NV]N;0#60R8F$N M?60K]PAR5"A++Z[ 8\(%)-XKO"\*PBKXV$Z=KZ"X%/HYA>(>-:8S M6SHDON;FP)B;8PBC AQ /M*BF4.#3<H0#&H5\%&""=QV\(A%SY-^2 M<[V.&.*2IXOH24-&S"!;2!X,O3CN?7=R,+G$M YFVH;%P+4H1& MB DL.W=E]M/4L5#TNY4P0,7A!K#_19RF2Z-7G'6 GWEYGND\1R!_9+ M(N<=D,26J[LL/M\&5PO=0KL&K?P$5(8N9=HH%#RWF$NM0]+9_&"\(1\M=D!" MKX[9%\Q60DK:43I5Y_,WIG[G!S6'1V,BV&*?!EFEY"^'-GZOT* " A@ M%0 '9T=G0M,C R,3$R,#%?;&%B+GAM;,V=76_CN!6&[POT/W#=FQ88QW&" M%DAV9A<93[(P-IMD8\]LVT6QH"7&$4*3 24G]K\O*8FR1/%(2HJ2G(L9C_@> MZJ7XF*2^CC_^N-M0]$)$FG#V:30].AXAPB(>)VS]:?1U,;Y8S.;S$4HSS&), M.2.?1HR/?OSASW]"\L_'[\9C=)40&I^C+SP:S]D#_Q[=X TY1S\11@3.N/@> M?<-TJ[;PJX02@69\\TQ)1F1!L>-S]/>CZ?$*C<<#ZOU&6,S%U_MY5>]CECVG MYY/)Z^OK$>,O^)6+I_0HXIMA%2XRG&W3JK;CW7'YIPC_2!/V=*[^6N&4('F\ M6'J^2Y-/([7?OIT=4-[,\VS_+%%*$T7"J-SV*,B#W0P58J+B M)XRL<49BM:,SM:/I/]2._E)NOL8K0D=(*24?8+O.&G6501/79N^(2'A\R=[G MVHSV9%]^=T3V/S2@'N^\"4N>8?HN\_5(Y[9OR/N.^"'._9&6XSQYWY&N1?Y? M;&=MRV\^O/;C2M7&:_FI89'L,CF!D5B;5%5TC,#Y'O*)H:R[JIU'C7JI&LVY M:+==S8QYG2F)CM;\91*31-9],E4?QNI#WFSYGS]F7*X$+E9I)G"4Z9KR9GP: M6J7N%CI*I:,-E0JUI")L_'4Q^B'7H-^UZC\?)X=:''2T M7 )M-X1E2UFCI07-8E?=;#.E>[E>%D0G6PR9?:PE2&D<=_"%W'&L=GY%\=IB MWRAWU<566[J/&X5!=++-D=G+E08ID:]N_D+22"3/:CG?U8Z&S'FG6TRV^KZF M"0N!MC&8A)K6T\!^3]:)FEJ4!75^2]3&CF$,T+L>^CMMFW.!51P$-$,<@K-% M/0A549XXNF!LB^D]>>:B"Y^FS#4U-I,F+'5-4(Q8C(%H%%I4B#T1\>M6GK$3 M0?>]4+24KKD K)IH&+*@Z+![ P&IY'X960K,TD0-8+V0M*7.3S< LZU3#T,7 M%"> .?B4I-+[)67Q2"A5]P,PZQ]0;&+7M,"&35[:RJ"( >V!S.01J P)!YO+ M%[4ZE\ND@8VMZ7W"T[+=Q4\E#A8AT^% BO(PI.(\D52[#='#4$OIFA[ JLF- M(0N*&+LWD)5"CG*]?T@N63P(D4KG!Q##IAV/4A0@'$UG?6A(M4\PKI(TPK3P MNEY?9> 9>HA M1K YILPM 7:330J:FH!(L!H#:#AH\V=*O1 QDR.3P'3.8K+[F>S!=K5T;ID M;#:A,$0!46%W!F!1BE&N1E+N!8P[D6RPV"^2J&>J: O=H@$9;;)AJ@*" [ & MT%&JT6(^\SF3+/%N'DM0DX>D>!Z\AQ)0[Q:6'MM-9@!Q0.AT.P0(DD&H&>43 MI#F+N'CFM<<=9GPK!\#]C,?P"J4GRBU4@YK01*LS)"# AO@$,&N$?BB>24%< MO<>35X!4#5Z(NXAC>:#2\I_KA)$IV'ZKUBU='7:;3%F$ 9$$NP/X*94?] >D M8M M"P6:DS^H?F="@TIT%#<_HN M:&3'>QUK9O+CK5CR5]O#V:#2"S)MJU9@#K+P<&EYZX-%!:CUC KQB4F^L+H5 M=X*_)"R"E\R0W LP@&DK-88V/'3L!OOXJ1;$.L[K6%,LRGN_)%KF9Y1IFK0/ M,84F/$B:QGH'ET+M$XD[GF:8_CMY[CP1MXN]X&$U;(6DH0P/%9N]/F"*&"2# M?)Q8E[BJ&QK65\F,O %ML'5X!KA4& 8'-4?L5X.+J22%RWULC"ZN&VHUO?(&?R 0%OBJJAPP9?9Z+D.YSM/5>)5A(K4/W[4R9S.[::>:R'5!$+UKNFE-T[K<<6_^)I), M[GG&-YLM*^_RV)X;!'2N>KG3INYQJRB(WN]R9I)0:E%3[!B+!:=)E&0)6_\B M3SY%@FVMLHE< 0$;U#2T%4&@ -HR.3@(D58ZAN!.$ 4AD1V1OP2H$@N)VX<' MZVS?)78%1;]A#0>L# *27GLF+#)@'-4B4!&"\AB_V,S3=$O$F^"QA'A""#0/ M@-32AX@39+(7JB+0)UL+$FWE_+B?GJR6249M)Y=MB;,Y"3!7S4A&>1!L *9, M%O(RQ!_0].2OJ[\A'>6X^V_X4F"5/':QWZPX!;)/656N(.BPJ#FP2() ?9E MTG##42E%A=9'=JJ&64MSC')7 %AMZ:YO% ;1Z39'K2]_HZ\]#?F7N^A1FB+ M"PEVF>NAWV;2'/[KFB 0Z##6.BDII4AK?;R0<)BRUOV+@+6W1<"Z9Q&P#G$1 ML!ZZ"%A[6P3HW18I0N2X=+NBR1H#R0D[U:ZAZ+!L\F&1!H4*[ \<,ZH0=(AQ MG=$R3W&FTO.+3;[_*_G!TDI YRRG99?-*JFE310$(UW.6FDMBZ1S-3%2:M=< M;.,D(W%AYBIAF$4)IE5Z1-L5\?X09[0,-%^!TZ,/@Z%A)ELX%6$ZEV$5>$AU MZ?I2>O$ QF^$TI\9?V4+@E/.2%Q<2['=*>K6NWUBIL=V\Z$90!P$3D,< H_. MJ*#QDXI".JR\$N:%I&^<;EF&1?XNN;"-3(#.+3F S28QAB@@4NS. $(J,2K4 M?E[0+K)'5(NLXG>'P 9"O:W>:-M[:MFH#8J;3(/0.=YGSX[ V+J(\O6*9 M$?5[$<=3XH;*?>*8EL5V[IA*$A >-E\=&60$TEHO+"PVF-+/VS1A)(4G(D/E ME@6KQ28+#4E +-A\ 2SD4J2U7EBXW!"QEM/;3X*_9H]E?E:P;8#:+1N=EIN, M6*4!L=+E#V!&AZ B1J?4]0//[I!0O,BR"+?4(G6,#6C68*:E"PD8R%R+%DHB M=;WEAF=HR='7E*#LD:#+\F?HZIG@BWI\_=)(%*D7(HI5.8NQL"'4)7;^JR.@ MX=9OC[2408#4:P_^'9(J ND0Q]3<2H9%_3PN-S'/R 9\VZ$_Q!5!0\UKCOKT M0= TT*3)5![6/+G. Y&*])G-J)[<'E[B-42.5\86@\;"N*8(@A'0%K0LKO]6 M@)_<>=L53:(KRC%\E:6A<9PQKVW/2)9W$ 1$0-L5E"(O%Z)3+7&Q@$A&]U"YWJI:A> 5JI9\3**M#OJA*4UV+[_?+ZIFOY26[6F^1?*YP2 MN>6_4$L#!!0 ( ""*@E-XE6UD60< .-7 5 =G1V="TR,#(Q,3(P M,5]P&ULS9Q-<]LV$(;OG>E_8-6S+$MNVMJQF[$5*Z.)$[N6D[2]9" 2 MDC & 0T ZN/?%R!%11\$N+YP[8,M4PM@WV=!D$L O'RW2GFTH$HS*:Y:W9/3 M5D1%+!,FIE>M+Z/V]:@_'+8B;8A(")>"7K6$;+W[Z^>?(OMS^4N['0T8YSJ.VFU O5^I2*3Z\CC0E^L-+MJN78WS2[/3J2:=GJGI]W./Y_N1O&, MIJ3-A.,6TU99RM525:Y[?G[>R;\M38\L5V/%RS;..J4[VYKMMRQ@O^.)9A^VS[LE*)ZT2?DY024X?Z21R?VWTMJTN MS,+,;$^9T\RP.(];Q]ET^M+V2^MP7GJFZ.2JY6QM([UNMW>:-_'KGI%9SVW_ MU,QUKU;4V6M^KJBFPN2*[^R!O2)T96ROHDE9D6O_A0X:9ER93=?I1FW7S[+4 M-FD_%I8;?TJ/N(SWG. N'O) <=FW<^J:QB=3N>@DE'4Z90Y?YTK[N)+ MW<'PN. I @1_ACE2!-4B1>!:B(SP1SJ7J@;\OB60]V^8O*NT(6'^.R/*4,77 M$-)'QD#8;S!A>Q0B\7Y21&CF^$" 'UL#B?^.>N/AT8B$?#2CG+N$C@A0+Z^R M!V+_ Q.[7^VF!L]\I L3_YVO!?Z06*0(/5#&9V$NZ K _,@92 M/\>D[E&(ROM6)%#:6U-P_H,/^T >$NH!TS'AA4<#>TR'<5>80Y&CY)RU,E&Q M_TN) D/?,88B1TE#:R0V#+R?*;7G3'!4\5M#D:,DH'4B&V9^*PPS:S<#\#E+ MQS\>G.ZS/K:",D9).GVB4-B63QJ$<1,;(;Z'EE#&*+EF2!P*Y[[5HP@?BH2N M/M)U"/21*90T2HX9E(>"^D&QE*CUB,7U@\:Q+10V2F89%HA"^XFLAHE5Q2:L MF!JLA^XM F6/DE:"Y**$8"ABJ>9RYW%Q7V;V?%SW91(ON)*OMH0T*8? M,!9Q=P\M?$N)#DR@?%%RU4HY32-U$5:4^+OOO@44*$H"6B6F89YWTLU]S*0( M/H\]MH)R1F+M/?5WO@:O8$,95@]E-(SQFV+&>M"7:9J)S3,: MSZR8QQ2*%R7]"\IK&/5(7UC#A!\4=9&F M]K8[7\?E-ARH^\G$-_*&[*'$47*]>J&XY(=:9U2]E']%*6@44-(^J.BFQQD: M9W;86W=[XR>W8\8SRAQ905FCI'P^40VS_2R?%'$[]T;K="RY?WM(I2&4,$J" M%Y#6,.0]/ZKQ'IA P:)D=I5RD,:$VU4\(V)*_:L7JBVA@%$RO9 XM+%W"AI[ MIR\<>U$R/I\H)+;%VG![1MV/.9L2_TZR8 'P/AM,X@&I3>_?R[?\N#W=*LW] M&-@/U=@]IE#@.%LD0_*:1ITES-"D<&G !!&Q3:FV^]H\V7E]*6@ 'W%H%& 7$.L48N2@B^2IY92BI?"*H\YX#' M%(H<<>[0(P]G[66QJ'E[[2E>WA$B[BL!!8\XB1@6B[0^S5#G,UO0]\20C8J@O!8T"2KH*%8US;=W9R1^\M.[907DC)J95PG#V3&5CSN(!ER1X M7[YG!N6+F(56R$+!>T/$L\KF)EX_*!E3ZJ9/]/9L R1$P J@(4',3U^$ N=Q M@4Q3MYE(QL^CF16M[S.3O\O4^A=\:! L!PT-YB9.@'"DNR#]8Z,736[6CW1" ME5NF\$17YL8V]!R^*0(4A\8']8U"8 P58;KL'.FZLP?^1_ M4$L! A0#% @ ((J"4R1_=G6A% _VH !( ( ! M &5H,C$P,C V.#$R7SAK+FAT;5!+ 0(4 Q0 ( ""*@E,M.LP#1RH !_- M 6 " =$4 !E:#(Q,#(P-C@Q,E]E>#$P,#$N:'1M4$L! M A0#% @ ((J"4^W<)ZLW P @P !$ ( !3#\ '9T M=G0M,C R,3$R,#$N>'-D4$L! A0#% @ ((J"4]G'I^K]"@ @(8 !4 M ( !LD( '9T=G0M,C R,3$R,#%?;&%B+GAM;%!+ 0(4 Q0 M ( ""*@E-XE6UD60< .-7 5 " >)- !V='9T+3(P D,C$Q,C Q7W!R92YX;6Q02P4& 4 !0!) 0 ;E4 end